| Investor Relations |

Five-Year Summary Mitsubishi Pharma Corporation and Consolidated Subsidiaries Millions of yen Thousands of U.S. dollars 2006 2005 2004 2003 2002 2006 Years ended March 31: Net sales  ¥ 236,207 ¥ 234,244 ¥ 235,431 ¥ 280,780 ¥ 228,983 $ 2,018,863 Cost of sales  81,444 81,712 83,812 120,736 105,272 696,102 Selling, general and   administrative expenses  118,528 121,483 122,892 130,596 103,746 1,013,060 Operating income  36,235 31,049 28,727 29,448 19,965 309,701 Net income  20,699 13,172 10,818 8,255 8,988 176,915   At March 31: Current assets  ¥ 205,342 ¥ 181,710 ¥ 179,363 ¥ 207,640 ¥ 218,296 $ 1,755,060 Property, plant   and equipment, net  77,309 84,546 87,060 105,375 104,787 660,761 Investments and other assets  24,401 24,372 29,777 27,760 29,481 208,555 Total assets  307,052 290,628 296,200 340,775 352,564 2,624,376 Current liabilities  57,573 63,911 65,619 117,309 128,101 492,077 Long-term liabilities  7,585 9,856 21,570 21,988 24,034 64,829 Minority interests  10,353 10,880 11,470 12,496 8,044 88,487 Shareholders’ equity  231,541 205,981 197,541 188,982 192,385 1,978,983 Yen U.S. dollars Amounts per share: Net income  ¥ 45.39 ¥ 29.02 ¥ 23.81 ¥ 18.05 ¥ 24.54 $ 0.39 Cash dividends applicable   to the year  20.44 10.00 10.00 10.00 11.00 0.17 Thousands of shares Common stock issued  458,435 458,435 458,435 458,435 458,435

| AR TOP | Profile Financial Highlights Message from the President > Business results Establishment of Joint Holding Company Launch of Joint Holding Company, Mitsubishi Chemical Holdings Corporation, from October 2005 Strengthening Pharmaceutical Business through Joint Holding Company Structure Meeting Tomorrow’s Challenge in Personalized Medicine Mid-term Corporate Action Plan Mid-term Corporate Action Plan — On Target Maximization of Sales and Marketing Strengths Optimization of Production and Technology Divisions Target of Total Cost Reduction Achieved Increasing the Certainty of Research and Development Results and Establishment of Global Marketing Basis R&D Strengthening Research and Development Product Pipeline Corporate Social Responsibility Improving Corporate Governance System Reinforced Implementation of Compliance Global Environmental Conservation: a Task for Every Individual Harmony with Society Financial Section Five-Year Summary Management’s Discussion and Analysis Balance Sheets Income Statements Shareholders’ Equity Cash Flows Notes Auditors’ Report Corporate Data Mitsubishi Chemical Holdings Corporation Investor Center

Copyright© Mitsubishi Pharma Corporation. All Rights Reserved.